You need to login...
If you are not registered...
| Subscribe to Cancer Stat: | |
|
or call us on: +44 (0)20 7769 6707 or email: apus@templetonapus.com |
|
Most viewed
- 1. Micronoma Raises $3M in Seed Funding
- 2. DDX39 Overexpression Predicts a Poor Prognosis and Promotes Aggressiveness of Melanoma by Cooperating With SNAIL
- 3. When Treatment Can't Be Delayed: Lung Cancer & COVID-19, What You Need to Know
- 4. 'Could I feel what they were doing? Yes': Rob Delaney on the pain and pleasure of his vasectomy
- 5. Valeo Pharma Commences Yondelis® Commercialization in Canada
- 6. DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer
- 7. FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol
- 8. Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)
- 9. Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer
- 10. [177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer.
Last updated at 4:13 GMT
Hot News Makers
Health/Pharma Companies
-
58638.06
-
46698.55
-
39226.19
-
36264.68
-
31212.88
-
14558.00
-
11992.58
-
11546.35
-
11124.80
-
10716.03
Last updated at 4:10 GMT
© Copyright 2020 Templeton Apus. All rights reserved.
Made with 
and
in the EU & the UK
and
in the EU & the UK